J&J Medical Connect
TREMFYA®

(guselkumab)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TREMFYA® (guselkumab)
Medical Information

TREMFYA - Occurrence of Headache in Adult Patients with Moderate to Severe Plaque Psoriasis or Active Psoriatic Arthritis

Last Updated: 08/27/2026

SUMMARY  

  • Please refer to local labeling for relevant information regarding the occurrence of headache with TREMFYA in adult patients with moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA).
  • Among phase 3 clinical trials evaluating TREMFYA in the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis, and moderately to severely active Crohn’s disease during the placebo-controlled period, headache was reported as a common adverse reaction. Common was defined as the frequency of the adverse reaction 1/100 or 1/10.1 
    • Patients with moderate to severe plaque PsO were evaluated from an analysis of two phase 3, randomized, double-blind, placebo- and adalimumab comparator-controlled studies (VOYAGE 1 and VOYAGE 2) designed to evaluate the safety and efficacy of TREMFYA.2,3 
    • Patients with active PsA were evaluated from an analysis of three phase 3, randomized, double-blind, placebo-controlled studies (DISCOVER-1, DISCOVER-2, and APEX) designed to evaluate the safety and efficacy of TREMFYA.4-6 

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 10 August 2026.

 

References

Show
1 Data on File. Guselkumab. Company Core Data Sheet v024. Janssen Research & Development, LLC. EDMS-ERI-111962822; 2026.  
2 Blauvelt A, Papp K, Griffiths C, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417.  
3 Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431.  
4 Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125.  
5 Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136.  
6 Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study. Ann Rheum Dis. 2025;84(12):1983-1994.  

Would you like to clear and leave your conversation? Message history will be lost.